Boceprevir, telaprevir, protease inhibitors of hepatitis C virus, orally active
| Author : Pierre Allain
||Date : 2010-10-25
Boceprevir and telaprevir are inhibitors of NS3 protease of hepatitis C virus. They are in clinical trials, and each is used in combination with peginterferon alpha and ribavirin. Their mechanism of action is comparable to that of inhibitors of the HIV protease.
The Lancet of August 28 2010 published the results of a clinical trial showing that the addition of boceprevir, 800 mg 3 times daily, to the standard treatment of chronic hepatitis C based on peginterferon alfa and ribavirin improves significantly their efficacy (sustained viral response) but induces many adverse effects, in particular anemia and taste disturbances.